Seed migration in prostate brachytherapy depends on experience and technique

Taussky, Daniel; Moumdjian, Camille; Larouche, R.; Béliveau-Nadeau, D.; Boudreau, Chantal; Hervieux, Yannick; Donath, David

doi:10.1016/j.brachy.2012.03.003

Cited by 23 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Depending in part on the method used to insert the seeds, their location within the prostate, the type of seed used, and the experience of the operator, embolization to the chest has been reported in between 1% and 55% of patients. 4,[11][12][13][14][15][16] It is important for physicians interpreting cardiac and thoracic imaging studies to be aware of both the potential for seed migration and the appearance of seeds, to avoid incorrectly attributing an embolized seed to another entity such as surgical material or other foreign metallic body.…”

Section: Discussionmentioning

confidence: 99%

Intracardiac Embolized Prostate Brachytherapy Seeds

Halpenny

Latson

Mason³

et al. 2016

Journal of Computer Assisted Tomography

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Intracardiac Embolized Prostate Brachytherapy Seeds

Halpenny

Latson

Mason³

et al. 2016

Journal of Computer Assisted Tomography

View full text Add to dashboard Cite

show abstract

“…It is possible that our procedures were suboptimal, and that this facilitated tumor migration to the lung. Taussky et al [19] reported the incidence of seed migration to decrease with accumulated experience. The overall incidence of seed migration was low, around 1%, in our series, and those with pulmonary metastases did not show evidence of seed migration.…”

Section: Discussionmentioning

confidence: 99%

Pulmonary Metastases After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer

et al. 2014

View full text Add to dashboard Cite

PurposeTo analyze unusual events and focus discussion on pulmonary metastasis in particular after low-dose-rate brachytherapy (LDR-BT) for prostate cancer (PCa).Materials and MethodsA total of 616 consecutive patients who had undergone LDR-BT for clinically localized PCa at Jikei University Hospital between October 2003 and April 2010 were enrolled in this study. Follow-up information was summarized, and patterns of biochemical recurrence and clinical outcome were investigated.ResultsDisease risk was stratified as low-risk in 231 patients, intermediate-risk in 365, and high-risk in 20, respectively. Of these patients, 269 (43.7%) had received hormonal therapy (HT) in combination with LDR-BT, and 80 (13.0%) had received external beam radiotherapy (EBRT). Average dosimetric parameter values with and without EBRT were 95.3% and 94.2% for V100, 132.8 Gy and 164.2 Gy for D90, and 180.6 Gy2 and 173.7 Gy2 for the biologically effective dose. Biochemical recurrence was noted in 14 patients (6.1%) in the low-risk group, 25 patients (6.8%) in the intermediate-risk group, and 6 patients (30.0%) in the high-risk group, respectively. In these cases of biochemical recurrence, 9 (64.3%), 13 (52.0%), and 4 patients (66.7%) in each respective risk group showed signs of clinical recurrence. Five patients (19.2%) with clinical recurrence developed pulmonary metastases, of which 4 were isolated lesions. All tumors responded favorably to subsequent HT.ConclusionsLDR-BT for biologically aggressive PCa may be linked to possible pulmonary metastasis owing to tumor dissemination during seed implantation. This information is important in planning adequate treatment for these patients.

show abstract

“…They demonstrated lower rates of secondary therapy for providers with an annual provider volume >10 cases and for those with a cumulative provider volume >200 cases. Taussky et al (12) showed that seed migration in prostate brachytherapy depended on experience and technique. Chen et al (13) concluded that patients treated with brachytherapy by higher-volume physicians were at lower risk for recurrence and prostate cancer death.…”

Section: Discussionmentioning

confidence: 99%

Diffusion pattern of low dose rate brachytherapy for prostate cancer in Japan

et al. 2013

View full text Add to dashboard Cite

Permanent implant brachytherapy for prostate cancer using iodine-125 seeds was adopted in Japan in 2003. Here, we report on the diffusion pattern of this treatment in Japan since 2003. We examined the annual numbers of prostate cancer patients per hospital in Japan, who were treated with iodine-125 seed implant brachytherapy with or without external beam radiation therapy between 2003 and 2011. The hospitals were excluded from the count if brachytherapy was begun in a hospital within the given year, and thus was only available for part of the year. W hen a medical technology, the usefulness of which has been established, is adopted in a country, how does the technology diffuse into medical practice? The speed and degrees of the diffusion depend upon many factors: consumer demand, promotional efforts of technology manufacturers, medical education, health insurance and payment systems, and governmental regulatory policies.

show abstract

Seed migration in prostate brachytherapy depends on experience and technique

Cited by 23 publications

References 18 publications

Intracardiac Embolized Prostate Brachytherapy Seeds

Intracardiac Embolized Prostate Brachytherapy Seeds

Pulmonary Metastases After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer

Diffusion pattern of low dose rate brachytherapy for prostate cancer in Japan

Contact Info

Product

Resources

About